Introduction
The antiphospholipid syndrome (APS), recognized as the most common acquired thrombophilia, is an autoimmune condition characterized by the occurrence of thrombotic events and/or pregnancy morbidity in individuals found to be persistently positive for antiphospholipid antibodies (aPL) [1] . The current classification criteria for APS include three laboratory tests:
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lupus anticoagulant (LA), anti-cardiolipin (aCL) and anti-b2 glycoprotein-I (b2GPI) antibodies. To prevent the detection of transient antibodies, tests must be positive on two separate occasions, at least 12 weeks apart [1] . APS can be associated with another autoimmune disease, mainly systemic lupus erythematosus, and has in the past been described as 'secondary' APS. On the other hand, APS can be found as an isolated condition called 'primary' APS (PAPS).
Thrombotic events in APS can affect the venous and the arterial system [1] . Whilst deep vein thrombosis represents the most frequent thrombotic feature of APS, arterial events include the potentially most lifethreatening manifestations of the syndrome, with the central nervous system the most common affected site [2, 3] . Ischaemic stroke involving the territory of the middle cerebral artery is the main neurological manifestation associated with APS [2] . However, transient ischaemic attack, amaurosis fugax, transient paresthesias, cerebral venous sinus thrombosis, ocular ischaemia and acute ischaemic encephalopathy have also been described [2, 4] .
Considering all patients with cerebral ischaemic events, the prevalence of aPL in young adults below the age of 50 has been reported to be as high as 17.2% (range 2%-56%) [5] . Given their young age and how the development of cerebrovascular events can negatively influence the quality of life, patients with aPL positivity represent a particular subgroup at greater risk of developing serious stroke and for whom the development of risk stratification models is necessary [5] .
To date, identifying patients with aPL positivity who are at high risk for developing any thrombotic event, including cerebrovascular manifestations, is still an unmet clinical need and remains a major challenge for the treating physicians.
Recently, our group developed a risk score for clinical manifestations of APS [the global APS score (GAPSS)] that takes into account the combination of conventional risk factors for cardiovascular events and the aPL profile [6] .
In this study, the aim was to prospectively identify predictive factors of ischaemic stroke in a cohort of PAPS patients with a clinical suspicion of acute stroke event and to further evaluate the rate of recurrence and/ or progression of cerebral lesions and potential new subclinical signs of infarction after 12 months of follow-up.
Patients and methods

Patients
This prospective multicentre study included 36 consecutive patients with known history of PAPS (either previous arterial or venous thrombotic events or pregnancy morbidity) attending the Giovanni Bosco Hospital, Turin, Italy, and the Louise Coote Lupus Unit at St Thomas' Hospital, London, UK, who presented with a new episode clinically suggestive of an acute stroke to our departments or the emergency departments within our hospitals (enrolment time January 2015-February 2017). The decision to conduct brain imaging was initiated by the emergency physician and it was based on the suspicion of an acute stroke. Every patient was additionally clinically assessed by a neurologist as per the standard of care in our two centres.
Study inclusion criteria comprised (i) the diagnosis of PAPS according to Sidney criteria [1] and (ii) the onset signs and/or symptoms of new focal neurological deficits suggestive of an acute stroke evaluated by a neurologist.
The indication for performing magnetic resonance imaging (MRI) was the suspicion of an acute cerebrovascular event following the National Institute for Health and Care Excellence (NICE) guidelines based on the onset of new focal neurological deficits [7] . The presence of concomitant or any previous history of headaches (including migraines with and without aura), cognitive impairment and self-reported wordfinding difficulties was recorded. The assessment for cerebral events included brain computed tomography, MRI, carotid ultrasound, electrocardiogram and echocardiography. Imaging findings were discussed in multidisciplinary meetings.
At admission, patients in the stroke group were screened for alternative aetiologies (e.g. substance abuse, carotid/vertebral artery dissections and cardio-embolic aetiology). In detail, after an initial brain MRI to confirm the ischaemic event, neck and cerebral vascular imaging (e.g. computed tomography angiography for head and neck), transthoracic echocardiogram with a bubble study, additional risk factor blood work (e.g. TSH, ESR, CRP, HIV and toxicology screen) and, when appropriate, sickle screen and pregnancy test were performed according to the treating physician's judgement.
Patients were followed up for 12 months. A followup cerebral MRI was performed after 12 months in all patients to assess the outcome of the abnormal findings reported in the first brain MRI and to investigate potential new subclinical signs of infarction.
Demographic, clinical and laboratory characteristics are summarized in Table 1 .
Cardiovascular risk factor assessment
Cardiovascular risk factors of the study population were assessed following the NICE guidelines [8] . In detail, enrolled patients underwent a physical examination, blood pressure determination and phlebotomy in order to assess vascular risk factors. Arterial hypertension was defined as an appropriately sized cut-off [8] , high blood pressure on at least two occasions and/ or use of oral antihypertensive medications. Serum total and high-density lipoprotein cholesterol levels were determined according to standardized methods and interpreted according to current cut-off values [8] .
Autoantibody detection
The aPL profile included LA, aCL and anti-b2GPI antibodies. The aCL and anti-b2GPI were detected by enzyme-linked immunosorbent assay (ELISA) as described previously [9, 10] . Plasma samples were tested for the presence of LA according to the recommended criteria from the International Society on Thrombosis and Haemostasis (ISTH) Subcommittee on Lupus Anticoagulant/Phospholipid-dependent Antibodies [11, 12] .
Adjusted GAPSS calculation
The cumulative adjusted GAPSS was calculated for each patient as previously reported, by adding together all points corresponding to the risk factors [6, 13] . After its first description, GAPSS was prospectively validated [14] and applied in a cohort of patients with PAPS [15] . To increase the generalizability of the findings, in this study an adjusted version of GAPSS (aGAPSS) was applied. This comprises only aPL testing included in the current classification criteria for APS (excluding antibodies antiphosphatidylserine/prothrombin (aPS/PT), not routinely available in all laboratories). Data are presented as aGAPSS. For the purpose of this study, all computed variables refer to values/parameters assessed at the time of the suspected stroke and after 12 months of follow-up.
Statistical analysis
Categorical variables are presented as number (%) and continuous variables are presented as mean (SD). The significance of baseline differences was determined by the chi-squared test, Fisher's exact test or the unpaired t test, as appropriate. A two-sided P value <0.05 was statistically significant. All statistical analyses were performed using SPSS version 19.0 (IBM, Armonk, NY, USA).
Results
A total of 36 consecutive PAPS patients [mean age 32 years (SD 33.7), 86% female] with suspect stroke were included in this prospective study. Twenty-five patients (69%) were <50 years old at the time of the first event. All patients fulfilled the current classification criteria for PAPS.
New focal neurological deficits were distributed as follows: six with dysphasia or dysarthria, four with self-reported speech disturbance, eight with subjective arm or leg weakness, 13 with subjective arm or leg paresthesia and 16 with new onset of severe headache.
Ischaemic stroke
In 10 patients (28%) [mean age 41 years (SD 13.4), 70% female] the suspicion of an acute ischaemic stroke was confirmed and MRI findings were compatible with a new ischaemic lesion. Demographics, cardiovascular risk factors and aPL profile at the time of the stroke are summarized in Table 2 . In the remaining 26 patients, the diagnosis of ischaemic stroke was ruled out after clinical and imaging evaluation.
When analysing for cardiovascular risk factors, hypercholesterolaemia was significantly higher in the patients with confirmed stroke compared to those without (chi-squared test: P < 0.05). No evidence of clinically significant large-artery atherosclerosis or cardioembolic aetiology was found in the 10 cases of ischaemic cerebrovascular events. Similarly, when evaluating the aPL positivity profiles in these two distinct groups, a significantly higher rate of anti-b2GPI antibodies (immunoglobulin G/immunoglobulin M) was found in patients with stroke (chi-squared test: P < 0.05). However, when focusing on the so-called triple positivity, no statistical difference was observed ( Table 2) . Significantly higher aGAPSS values were seen in patients with stroke [mean aGAPSS 8.9 (SD 4.7) vs. mean aGAPSS 6.4 (SD 2.5); t test P < 0.05].
No statistically significant differences were observed when comparing each cardiovascular risk factor separately (i.e. smoking, diabetes, arterial hypertension) or other thrombotic risk factors (hormonal therapy, immobilization, surgery or malignancy).
Due to previous thrombosis, 25 patients were receiving oral anticoagulation with vitamin K antagonists (VKA). Of those 25 patients, 20 patients suffered previous deep vein thrombosis and were treated with VKA with a target international normalized ratio (INR) of 2-3; out of five patients with previous arterial thrombosis, three were treated with VKA with a target INR of 2-3 plus low dose aspirin (LDA) and two patients were treated with VKA and a target INR between 3-4. Moreover, three patients were treated with low molecular weight heparin (two patients because of pregnancy and one patient for secondary thromboprophylaxis whilst being treated with chemotherapy for breast cancer). Eight patients with a previous history of obstetric APS were receiving anti-platelet agents.
Out of the 10 patients in whom the suspected stroke was confirmed, eight had a history of previous venous thrombosis and were receiving VKA, INR target 2-3, one patient had a history of an arterial event and was treated with VKA, INR 2-3, plus LDA and one patient had a history of previous pregnancy complication and received LDA. For patients receiving therapy with VKA, the mean time in therapeutic range (TTR) calculated over the previous 6 months before the new cerebrovascular event was 77.7% (SD 6.6%).
A tight control of cardiovascular risk factors and treatment implementation with statins and/or antihypertensive agents was ensured for all the patients and monitored by the treating physician's judgement. Therapeutic goals were set according to current recommendations [16, 17] .
Evaluation at 12 months of follow-up
During the 12 months of follow-up, no patient developed new episodes clinically suggestive of cerebral ischaemia. In the non-stroke group, no changes at the follow-up MRI were observed compared to the baseline investigation.
After the diagnosis of stroke, 9/10 patients were started/continued on anticoagulation therapy with VKA INR 2-3 plus LDA. The patient with a previous arterial event was continued on VKA, increasing the INR target to 3-4. In agreement with the stroke unit team, one patient (with previous history of obstetric APS and subsequent stroke) was initially treated with VKA plus LDA but had to be switched to dual anti-platelet agents (LDA + clopidogrel) after 3 months of VKA treatment because of unsatisfactory TTR, poor compliance and poor adherence on medical appointments.
After 12 months of follow-up, the nine patients on VKA treatment showed no sign of cerebral progression based on new brain MRI. VKA was well tolerated and no adverse event was reported.
The one patient only treated with anti-platelet agents presented progression of the cerebral lesions as assessed after multidisciplinary panel evaluation. More specifically, at the brain MRI examination, a significant progression of the previously known lacunar infarctions involving the posterior limb of the left internal capsule/lateral thalamus and left frontal subcortical white matter was observed.
Other cardiovascular risk factors were managed according to the treating physician's judgement.
Discussion
This prospective multicentre study assessed predictive factors for stroke in a cohort of 36 PAPS patients presenting with the onset of signs and/or symptoms of new focal neurological deficits suggestive of an acute stroke.
It was found that 10 patients (28%) had a confirmed diagnosis of acute ischaemic cerebrovascular event. When stratifying patients for age, 6/10 patients with a documented stroke at the brain MRI scan belonged to the younger subgroup of patients (<50 years old). Moreover, patients who experienced a stroke were receiving treatment according to the current recommendations. TTR for the patients treated with VKA as secondary thromboprophylaxis was 77.7%. Our results highlight the fact that, despite being treated with anticoagulation (VKA treatment), patients with thrombotic PAPS still represent a subgroup of patients at high risk for thrombosis recurrences.
The identification of patients with aPL, who are at greater risk for developing any thrombotic event, i.e. especially arterial cerebral thrombosis, is still an unmet need. Therefore, risk stratifying in these patients remains crucial in this setting.
In our prospective study, the clinical relevance of the aGAPSS for risk stratification in PAPS patients with stroke was demonstrated. In fact, significantly higher values of aGAPSS were found in patients with stroke. The results are in line with a very recent study from our group showing higher aGAPSS values in patients who experienced acute myocardial infarction compared to those with other thrombosis [18] .
Recently, a variety of prediction models for cardiovascular disease have been developed mainly focusing on stroke or ischaemic heart events. Amongst others, Hajifathalian and colleagues [19] elaborated a well thought out cardiovascular disease risk equation (Globorisk), adjusted for country of origin, with routinely available information. Their risk score is based primarily on age, country of origin, arterial hypertension, smoking and diabetes. Although promising, such score does not seem applicable to patients with autoimmune disorders, especially a rare disorder such as PAPS. In fact, in our cohort 15 patients out of 36 (42%) were younger than 40 years old and the Globorisk can therefore not be applied. Furthermore, just a portion of patients had diabetes (two out of 36; 6%) and/or arterial hypertension (nine out of 36; 25%).
Whilst anti-platelet agents are the gold standard therapies in stroke, patients with APS have been shown to benefit from long term anticoagulation [20] . Indeed, the only patient in our cohort who suffered with a progression of the ischaemic cerebral lesion at MRI, after 12 months follow-up, was the one not treated with VKA.
When referring to the putative aetiology of the stroke, patients were screened according to the treating physician's judgement and no significant causes rather than the presence of aPL and the described cardiovascular risk factors were identified. It was outside the scope of this study to assess the clinical accuracy of previously proposed systems for the aetiological classification of ischaemic stroke in patients with aPL (e.g. the TOAST, Causative Classification of Stroke and ASCO systems [21] [22] [23] ). However, patients with confirmed events could be categorized as having 'acute stroke of other determined aetiology' according to the TOAST classification [21] , as this category includes patients with more rare causes of stroke such as non-atherosclerotic vasculopathies or hypercoagulable states or haematological disorders.
This study presents some limitations. First, the sample size is small, mainly due to the low prevalence of PAPS in the general population. Secondly, anticoagulant treatments before the cerebrovascular event and other cardiovascular risk factor treatment were based on the treating physician's judgement. Thirdly, the previous medical history of PAPS patients was heterogeneous, including venous and arterial thrombosis and obstetric APS.
Summary
In summary, whilst acknowledging its limitations, this study contains some important clinical messages: PAPS is a thrombophilia with a high rate of recurrences; cerebrovascular events such as stroke affect a younger population compared with the non-APS population; a risk assessment, using appropriate tools such as aGAPSS, should be implemented to identify those patients at a higher risk of recurrences and have a strict control of all modifiable risk factors for cardiovascular events.
